Unveiling the heritability of selected unexplored pharmacogenetic markers in the Saudi population
This study provides novel insights into the distribution of clinically relevant PGx variants in the Saudi population. The findings have implications for personalizing treatments for various conditions, including rheumatoid arthritis, cystic fibrosis, and hepatitis C. These data contribute to the development of population-specific PGx testing panels and treatment guidelines.
Authors
- Mohammad A. Alshabeeb (ORCID: https://orcid.org/0000-0002-8885-6254)
- Deemah Alwadaani
- Sireen Abdul Rahim Shilbayeh (ORCID: https://orcid.org/0000-0002-5020-6838)
- Fatemah A. Alherz (ORCID: https://orcid.org/0000-0002-6877-5158)
- Ali Alghubayshi
Institutions
- Princess Nourah bint Abdulrahman University (SA)
- Virginia Commonwealth University (US)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- University of Ha'il (SA)
- King Abdullah International Medical Research Center (SA)
- Genomics Medicine (Ireland) (IE)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.3389/fphar.2025.1559399
- Citations
- 1
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 1.56
Funders
- Princess Nourah Bint Abdulrahman University
- King Abdullah International Medical Research Center